Latest & greatest articles for magnesium

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on magnesium or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on magnesium and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for magnesium

101. Magnesium sulphate in the management of patients with aneurysmal subarachnoid haemorrhage: a meta-analysis of prospective controlled trials

Magnesium sulphate in the management of patients with aneurysmal subarachnoid haemorrhage: a meta-analysis of prospective controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

102. Antenatal magnesium sulfate and neurologic outcome in preterm infants: a systematic review (PubMed)

Antenatal magnesium sulfate and neurologic outcome in preterm infants: a systematic review To systematically review rates of neurologic outcomes reported in childhood for the preterm fetus exposed to antenatal magnesium sulfate.We searched the Cochrane Pregnancy and Childbirth Group's Trials Register, CENTRAL (The Cochrane Library 2008, Issue 3), relevant references from retrieved articles, and abstracts submitted to major congresses.We sought all randomized controlled trials (RCTs (...) ) of antenatal magnesium sulfate with neurologic outcomes reported for the fetus.Five eligible RCTs with 6,145 fetuses were identified; in four studies (4,446 fetuses) the primary intent was neuroprotection of the fetus. Methods of the Cochrane Collaboration were used to analyze the data. Antenatal magnesium sulfate therapy given to women at risk of preterm birth substantially reduced the risk of cerebral palsy in their children (relative risk [RR] 0.69; 95% confidence interval [CI] 0.54-0.87; five trials

2009 EvidenceUpdates

103. Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks` gestation: a systematic review and metaanalysis (Full text)

Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks` gestation: a systematic review and metaanalysis We conducted a systematic review and metaanalysis of randomized controlled trials to determine whether magnesium sulfate administered to women at risk of preterm delivery before 34 weeks of gestation may reduce the risk of cerebral palsy in their children. Six trials involving 4796 women and 5357 infants were included. Antenatal magnesium (...) sulfate was associated with a significant reduction in the risk of cerebral palsy (relative risk [RR], 0.69; 95% confidence interval [CI], 0.55-0.88), moderate or severe cerebral palsy (RR, 0.64; 95% CI, 0.44-0.92), and substantial gross motor dysfunction (RR, 0.60; 95% CI, 0.43-0.83). There was no overall difference in the risk of total pediatric mortality (RR, 1.01; 95% CI, 0.89-1.14). Minor side effects were more frequent among women receiving magnesium sulfate. In conclusion, magnesium sulfate

2009 EvidenceUpdates PubMed

104. Magnesium sulfate in severe perinatal asphyxia: a randomized, placebo-controlled trial (PubMed)

Magnesium sulfate in severe perinatal asphyxia: a randomized, placebo-controlled trial The goal was to study whether postnatal magnesium sulfate infusion could improve neurologic outcomes at discharge for term neonates with severe perinatal asphyxia.Forty term (> or =37 weeks of gestation) neonates with severe perinatal asphyxia were studied in a prospective, longitudinal, placebo-controlled trial. Patients were assigned randomly to receive either 3 doses of magnesium sulfate infusion at 250 mg (...) of 20) of patients had severe encephalopathy. The mean serum magnesium concentration in the treatment group remained at > or =1.2 mmol/L for 72 hours after the first infusion. At discharge, 22% (4 of 18) of infants in the treatment group had neurologic abnormalities, compared with 56% (10 of 18) of infants in the placebo group. Also, neuroimaging (head computed tomography) performed on day 14 yielded abnormal findings for fewer infants in the treatment group than in the placebo group (16% vs 44

2009 EvidenceUpdates

105. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. (PubMed)

Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Epidemiological and basic science evidence suggests that magnesium sulphate before birth may be neuroprotective for the fetus.To assess the effects of magnesium sulphate as a neuroprotective agent when given to women considered at risk of preterm birth.We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (31 August 2008).Randomised controlled trials of antenatal magnesium sulphate (...) therapy in women threatening or likely to give birth at less than 37 weeks' gestational age. For one subgroup analysis, studies were broadly categorised by the primary intent of the study into "neuroprotective intent", or "other intent (maternal neuroprotective - pre-eclampsia)", or "other intent (tocolytic)".At least two authors assessed trial eligibility and quality, and extracted data.Five trials (6145 babies) were eligible for this review. Antenatal magnesium sulphate therapy given to women

2009 Cochrane

106. The Efficacy of Administration of Intravenous Magnesium Sulfate for Improved Ventricular Rate Control or Rhythm Control in Patients with Non-postoperative Atrial Fibrillation and Atrial Flutter

The Efficacy of Administration of Intravenous Magnesium Sulfate for Improved Ventricular Rate Control or Rhythm Control in Patients with Non-postoperative Atrial Fibrillation and Atrial Flutter "The Efficacy of Administration of Intravenous Magnesium Sulfate for Im" by Mary Schindeler < > > > > > Title Author Date of Graduation 8-15-2009 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Annjanette Sommers MS, PA-C Second Advisor Rob Rosenow (...) PharmD, OD Rights . Abstract INTRODUCTION: Standard treatment for atrial tachyarrthmias, such as atrial fibrillation or atrial flutter, involves rate and rhythm control. Previous studies have looked at the electrophysiologic effects of magnesium on impulse formation and propagation, and theorized it could be beneficial in treatment for atrial tachycardias. There recently have been studies about magnesium sulfate and its utility in establishing rate and rhythm control in patients with atrial

2009 Pacific University EBM Capstone Project

107. Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks' gestation: a systematic review and metaanalysis (Full text)

Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks' gestation: a systematic review and metaanalysis Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks' gestation: a systematic review and metaanalysis Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks' gestation: a systematic review and metaanalysis Conde-Agudelo A, Romero R CRD summary (...) This well-conducted review concluded that magnesium sulphate administered to women at risk of delivery before 34 weeks of gestation reduced the risk of cerebral palsy in their children. The authors' conclusions are likely to be reliable. Authors' objectives To determine the efficacy and safety of antenatal magnesium sulphate administered to women at risk of pre-term delivery before 34 weeks of gestational age for the prevention of cerebral palsy in their children. Searching PubMed, EMBASE, CINAHL

2009 DARE. PubMed

108. Magnesium sulphate effective neuroprotection for the foetus of women at risk of preterm delivery

Magnesium sulphate effective neuroprotection for the foetus of women at risk of preterm delivery PEARLS Practical Evidence About Real Life Situations PEARLS are succinct summaries of Cochrane Systematic Reviews for primary care practitioners. They Magnesium sulphate effective neuroprotection for the foetus of women at risk of preterm delivery Clinical question How effective is magnesium sulphate as a neuroprotective agent when given to women considered at risk of preterm delivery? Bottom line (...) Antenatal magnesium sulphate therapy given to women at risk of preterm delivery, substantially reduced the risk of cerebral palsy in their child (NNT* 63). There was also a significant reduction in the rate of substantial gross motor dysfunction. The loading dose given was 4g or 6g IV, with a maintenance dose varying from nil (2 studies) to 1g/hour (1 study) and 2-3 g/hour (2 studies). The magnesium sulphate was given 24 hours prior to delivery in 3 studies, with no specific time interval reported in 2

2009 Cochrane PEARLS

109. Review: antenatal magnesium sulphate prevents cerebral palsy in preterm infants

Review: antenatal magnesium sulphate prevents cerebral palsy in preterm infants Review: antenatal magnesium sulphate prevents cerebral palsy in preterm infants | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional (...) accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: antenatal magnesium sulphate prevents cerebral palsy in preterm infants Article Text Therapeutics Review: antenatal magnesium sulphate prevents cerebral palsy in preterm infants Statistics from Altmetric.com Question

2009 Evidence-Based Medicine (Requires free registration)

110. A meta analysis of treating subarachnoid hemorrhage with magnesium sulfate

A meta analysis of treating subarachnoid hemorrhage with magnesium sulfate Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

111. Effects of antenatal exposure to magnesium sulfate on neuroprotection and mortality in preterm infants: a meta-analysis

Effects of antenatal exposure to magnesium sulfate on neuroprotection and mortality in preterm infants: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

112. Magnesium for acute traumatic brain injury. (PubMed)

Magnesium for acute traumatic brain injury. Acute traumatic brain injury is a leading cause of death and disability in young adults. Numerous pharmacological and non-pharmacological tools have been investigated and considered as potential mechanisms for improving neurological outcome. Magnesium has been considered as one of these potential therapeutic tools because of its activity on NMDA-receptors, calcium channels and neuron membranes. Animal studies have indicated a beneficial effect (...) of magnesium on outcome after brain injury, but its efficacy in humans is unknown.To quantify the effect of magnesium administration on mortality and morbidity in patients with acute traumatic brain injury.We searched the Cochrane Injuries Group's specialised register, Cochrane Central Register of Controlled Trials, CENTRAL (The Cochrane Library issue 2, 2008), MEDLINE (and PubMed to 28 May, 2008: last 60 days), EMBASE, National Research Register, Current Controlled Trials, SIGLE, LILACS, and Zetoc

2008 Cochrane

113. Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation

Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page (...) not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Study found that further research is needed to provide stronger evidence for the optimum delivery of intravenous magnesium sulphate to patients undergoing a coronary artery bypass graft to prevent atrial fibrillation. {{author

2008 NIHR HTA programme

114. Intraarticular injection of magnesium sulphate and/or bupivacaine for postoperative analgesia after arthroscopic knee surgery (Full text)

Intraarticular injection of magnesium sulphate and/or bupivacaine for postoperative analgesia after arthroscopic knee surgery Intraarticular bupivacaine is often used for prevention of pain after arthroscopic knee surgery. Intraarticular magnesium, a N-methyl-D-aspartate receptor blocker, would be of particular interest in either producing postoperative analgesia or enhancing the analgesic effect of intraarticular bupivacaine. We designed this study to determine whether intraarticular magnesium (...) sulfate or bupivacaine results in a decrease in visual analog scale (VAS) score followed by a decrease in analgesic requirement and whether their combination would provide more reduction in VAS, and subsequently less analgesic requirement, than either drug alone.One-hundred and eight patients undergoing arthroscopic meniscectomy were randomized blindly into one of four parallel groups. The saline placebo group (group S) received 20 mL of isotonic saline, and the magnesium group (group M) received 20

2008 EvidenceUpdates PubMed

115. Nexium (esomeprazole magnesium) For Delayed-Release Oral Suspension

Nexium (esomeprazole magnesium) For Delayed-Release Oral Suspension Drug Approval Package: Nexium (esomeprazole magnesium) NDA #022101 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Nexium (esomeprazole magnesium) For Delayed-Release Oral Suspension Company: AstraZeneca LP Application No.: 022101 Approval Date: 2/27/2008 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF

2008 FDA - Drug Approval Package

116. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. (Full text)

A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. Research suggests that fetal exposure to magnesium sulfate before preterm birth might reduce the risk of cerebral palsy.In this multicenter, placebo-controlled, double-blind trial, we randomly assigned women at imminent risk for delivery between 24 and 31 weeks of gestation to receive magnesium sulfate, administered intravenously as a 6-g bolus followed by a constant infusion of 2 g per hour, or matching (...) placebo. The primary outcome was the composite of stillbirth or infant death by 1 year of corrected age or moderate or severe cerebral palsy at or beyond 2 years of corrected age.A total of 2241 women underwent randomization. The baseline characteristics were similar in the two groups. Follow-up was achieved for 95.6% of the children. The rate of the primary outcome was not significantly different in the magnesium sulfate group and the placebo group (11.3% and 11.7%, respectively; relative risk, 0.97

2008 NEJM PubMed

117. Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation

Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation Shepherd J (...) , Jones J, Frampton G K, Tanajewski L, Turner D, Price A CRD summary RCTs directly comparing intravenous magnesium sulphate with sotalol were not identified, but the authors did conclude that intravenous magnesium is effective in preventing atrial fibrillation in patients undergoing coronary artery bypass graft when compared to controls. This was a well conducted piece of research, which considered limitations with the included studies. The authors' conclusions are likely to be reliable. Authors

2008 DARE.

118. Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation

Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation Shepherd J (...) , Jones J, Frampton GK, Tanajewski L, Turner D, Price A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Shepherd J, Jones J, Frampton GK, Tanajewski L, Turner D, Price A. Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation. Southampton

2008 Health Technology Assessment (HTA) Database.

119. Magnesium sulfate for persistent pulmonary hypertension of the newborn. (PubMed)

Magnesium sulfate for persistent pulmonary hypertension of the newborn. Persistent pulmonary hypertension of the newborn (PPHN) occurs in approximately 1.9 per 1000 newborns and may be more frequent in developing countries. There is strong evidence for the use of inhaled nitric oxide (iNO) and extra corporeal membrane oxygenation (ECMO) in the treatment of PPHN. However, many developing countries do not have access or the technical expertise required for these expensive therapies. Magnesium (...) sulfate is a potent vasodilator and hence has the potential to reduce the high pulmonary arterial pressures associated with PPHN. If magnesium sulfate were found to be effective in the treatment of PPHN, this could be a cost effective and potentially life-saving therapy.To evaluate the use of magnesium sulfate compared with placebo or standard ventilator management alone, sildenafil infusion, adenosine infusion, or inhaled nitric oxide on mortality or the use of backup iNO or ECMO in term and near

2007 Cochrane

120. Intravenous magnesium for acute myocardial infarction. (Full text)

Intravenous magnesium for acute myocardial infarction. Mortality and morbidity from acute myocardial infarction (AMI) remain high. Intravenous magnesium started early after the onset of AMI is thought to be a promising adjuvant treatment. Conflicting results from earlier trials and meta-analyses warrant a systematic review of available evidence.To examine the effect of intravenous magnesium versus placebo on early mortality and morbidity.We searched CENTRAL (The Cochrane Library Issue 3, 2006 (...) ), MEDLINE (January 1966 to June 2006) and EMBASE (January 1980 to June 2006), and the Chinese Biomedical Disk (CBM disk) (January 1978 to June 2006). Some core Chinese medical journals relevant to the cardiovascular field were hand searched from their starting date to the first-half year of 2006.All randomized controlled trials that compared intravenous magnesium with placebo in the presence or absence of fibrinolytic therapy in addition to routine treatment were eligible if they reported mortality

2007 Cochrane PubMed